Table 3.
Summary of complications data for living donor and deceased donor kidney transplants using rapid discontinuation of prednisone for maintenance immunosuppression with and without pretransplant diabetes
| 1-/5-/10-year rates (%) | ||
|---|---|---|
| Recipients with Diabetes | Recipients without Diabetes | |
| Complication rate after LD transplant | ||
| NODM | — | 2/4/7a |
| cataracts | 4/11/17a | 0.7/2/4a |
| fracture | 4/16/33 | 1/5/10 |
| AVN | 0/0/1 | 0/0.4/3b |
| CMV infection | 7/16/22 | 8/11/12a |
| PTLD | 0.3/0.3/0.3 | 0/0.6/2 |
| non-PTLD malignancy | 0/3/11 | 1/6/13 |
| Complication rate after DD transplant | ||
| NODM | — | 4/11/11a |
| cataracts | 1/5/9a | 0/2/7a |
| fracture | 6/15/23 | 3/7/9 |
| AVN | 0/0.5/6 | 0/0.6/0.6a |
| CMV infection | 13/15/21b | 14/19/21 |
| PTLD | 1/3/6 | 0.5/1/1 |
| non-PTLD malignancy | 3/10/13 | 1/2/8 |
NODM, new-onset diabetes mellitus; AVN, avascular necrosis; CMV, cytomegalovirus; PTLD, post-transplant lymphoproliferative disease.
a
P<0.001 (vs. historical control).
b
P<0.05 (vs. historical control).